ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 012,37
0,24%
Dow Jones
38 544,58
-0,37%
DAX
18 630,78
0,80%
Brent Oil
78,995
-2,24%
Bitcoin
69 116,55
2,02%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ESSA Pharma Inc (EPIX)

  7. ESSA Pharma Inc (EPIX) Actualités

EPIX ESSA Pharma Inc

6,675
-0,075 (-1,11%)
Dernière mise à jour : 16:30:32
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
ESSA Pharma Inc EPIX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,075 -1,11% 6,675 16:30:32
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
6,82 6,605 6,82 6,75
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/5/202414:00PRNUSESSA Pharma to Present at the Jefferies Global Healthcare..
14/5/202413:01EDGAR2Form 8-K - Current report
14/5/202413:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202413:00PRNUSESSA Pharma Provides Corporate Update and Reports Financial..
06/5/202423:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/4/202414:00PRNUSESSA Pharma to Present at the 2024 Bloom Burton & Co...
08/3/202402:13PRNCAESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING..
07/3/202423:18EDGAR2Form 8-K - Current report
06/3/202400:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202413:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/2/202413:01EDGAR2Form 8-K - Current report
13/2/202413:00PRNUSESSA Pharma Provides Corporate Update and Reports Financial..
07/2/202417:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202414:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202414:00PRNUSESSA Pharma to Present at the Oppenheimer 34th Annual..
29/1/202415:15EDGAR2Form 8-K - Current report
26/1/202422:40EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/1/202422:27EDGAR2Form DEF 14A - Other definitive proxy statements
25/1/202416:00PRNUSESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386)..
23/1/202422:09EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202402:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202422:19EDGAR2Form 144 - Report of proposed sale of securities
16/1/202419:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202402:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:04EDGAR2Form 144 - Report of proposed sale of securities
12/12/202313:01EDGAR2Form 8-K - Current report
12/12/202313:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
12/12/202313:00PRNUSESSA Pharma Provides Corporate Update and Reports Financial..
24/11/202317:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202314:00PRNCAESSA Pharma to Present at the Piper Sandler 35th Annual..
08/11/202314:00PRNCAESSA Pharma to Present at the Jefferies London Healthcare..
06/11/202323:51PRNCAESSA Pharma Enters into At-The-Market Equity Offering Sales..
06/11/202322:57EDGAR2Form 8-K - Current report
26/10/202323:41PRNCAESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386)..
23/10/202322:19EDGAR2Form 8-K - Current report
21/10/202315:00PRNUSESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386)..
11/10/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
03/10/202322:35EDGAR2Form S-3/A - Registration statement under Securities Act of..
19/9/202322:43EDGAR2Form S-3 - Registration statement under Securities Act of..
18/9/202313:05EDGAR2Form 8-K - Current report
18/9/202313:00PRNUSESSA Pharma Announces Initiation of Phase 2 Study Evaluating..
31/8/202313:00PRNUSESSA Pharma Insiders Establish Automatic Securities..
08/8/202313:15EDGAR2Form 8-K - Current report
08/8/202313:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:00PRNCAESSA Pharma Provides Corporate Update and Reports Financial..
06/6/202313:00PRNUSESSA Pharma Appoints Lauren Merendino to its Board of..

Dernières Valeurs Consultées

NASDAQ
EPIX
ESSA Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés